Citius Oncology, Inc.
NASDAQ:CTORDrug Manufacturers - General
+$0.03 today
- Market cap
- $51.83M
- Beta
- 3.42
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$0.42
Volume 0.15M
Average 0.12M
CTOR Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Citius Oncology, Inc.NASDAQ: CTOR
Operating Margin · Q2 FY2026 · quarter ended Mar 2026
Operating margin at -1716.2%
Operating margin was -1716.2% in Q2 FY2026. On a trailing-twelve-month basis it was -775.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Margin history
Percent of revenue · from the income statement
No Operating Margin data reported for this period type.
Operating Margin vs competitors
How CTOR compares with its peers on the latest reported figures
- CTOR's LTM Mar 2026 operating margin of -775.6% is the 4th highest of the 7 companies compared; the peer median is -422.9%.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 24.7% | +190.9 pp | +86.8 pp | |
| LTM Mar 2026 | -10.3% | +9.9 pp | +114.5 pp | |
| LTM Mar 2026 | -28.7% | -11.8 pp | +15.0 pp | |
CTORCitius Oncology, Inc. | LTM Mar 2026 | -775.6% | — | — |
| LTM Mar 2026 | -817.1% | -636.0 pp | -767.0 pp | |
| LTM Mar 2026 | -2207.5% | -704.0 pp | -1902.2 pp | |
| LTM Mar 2026 | -7641.0% | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
ACTUActuate Therapeutics Inc | FY2025 | — | — | — |
| Peer median (excluding CTOR) | -422.9% | -11.8 pp | +15.0 pp | |
Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — |
| Research & Development | 6.86M | 4.24M | 4.93M | 6.42M |
| Selling, General & Admin | 2.86M | 7.88M | 15.65M | 17.1M |
| Operating Expenses | 9.71M | 12.12M | 20.57M | 23.52M |
| Depreciation & Amortization | 9.71M | 0 | 0 | 0 |
| EBITDA | 0 | (12.12M) | (20.57M) | (23.49M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (9.71M) | (12.12M) | (20.57M) | (23.52M) |
| Operating Margin | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 36.37K |
| Interest Expense | 0 | 0 | 0 | 218.03K |
| Other Income / Expenses | 0 | 0 | 0 | (181.66K) |
| Income Before Tax | (9.71M) | (12.12M) | (20.57M) | (23.7M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 1.15M | 576K | 576K | 1.06M |
| Net Income | (10.87M) | (12.7M) | (21.15M) | (24.76M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.08) | (0.19) | (0.30) | (0.34) |
| EPS (Diluted) | (0.08) | (0.19) | (0.30) | (0.34) |
| Weighted Avg Shares | 90.16M | 89.48M | 71.55M | 73.27M |
| Weighted Avg Shares (Diluted) | 90.16M | 89.48M | 71.55M | 73.27M |
Citius Oncology, Inc.
NASDAQ:CTOR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.